AstraZeneca PLC (AZNCF)
130.24
+1.04
(+0.80%)
USD |
OTCM |
Nov 14, 16:00
AstraZeneca Enterprise Value: 227.21B for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 227.21B |
| November 13, 2024 | 225.60B |
| November 12, 2024 | 224.38B |
| November 11, 2024 | 221.88B |
| November 08, 2024 | 223.33B |
| November 07, 2024 | 221.50B |
| November 06, 2024 | 221.47B |
| November 05, 2024 | 228.45B |
| November 04, 2024 | 246.11B |
| November 01, 2024 | 246.76B |
| October 31, 2024 | 245.29B |
| October 30, 2024 | 257.07B |
| October 29, 2024 | 257.30B |
| October 28, 2024 | 255.67B |
| October 25, 2024 | 255.67B |
| October 24, 2024 | 260.48B |
| October 23, 2024 | 261.46B |
| October 22, 2024 | 267.76B |
| October 21, 2024 | 265.03B |
| October 18, 2024 | 270.06B |
| October 17, 2024 | 264.85B |
| October 16, 2024 | 263.58B |
| October 15, 2024 | 263.58B |
| October 14, 2024 | 253.77B |
| October 11, 2024 | 253.77B |
| Date | Value |
|---|---|
| October 10, 2024 | 253.77B |
| October 09, 2024 | 255.75B |
| October 08, 2024 | 255.75B |
| October 07, 2024 | 266.71B |
| October 04, 2024 | 261.97B |
| October 03, 2024 | 262.18B |
| October 02, 2024 | 271.70B |
| October 01, 2024 | 266.40B |
| September 30, 2024 | 264.76B |
| September 27, 2024 | 264.76B |
| September 26, 2024 | 262.96B |
| September 25, 2024 | 262.96B |
| September 24, 2024 | 256.82B |
| September 23, 2024 | 265.81B |
| September 20, 2024 | 265.81B |
| September 19, 2024 | 269.83B |
| September 18, 2024 | 279.50B |
| September 17, 2024 | 269.94B |
| September 16, 2024 | 268.69B |
| September 13, 2024 | 270.46B |
| September 12, 2024 | 267.73B |
| September 11, 2024 | 273.72B |
| September 10, 2024 | 273.72B |
| September 09, 2024 | 273.47B |
| September 06, 2024 | 287.26B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
112.53B
Minimum
Mar 13 2020
296.60B
Maximum
Aug 30 2024
202.88B
Average
214.31B
Median
Oct 23 2023
Enterprise Value Benchmarks
| Adaptimmune Therapeutics PLC | -38.64M |
| Biodexa Pharmaceuticals PLC | -3.088M |
| Verona Pharma PLC | 2.678B |
| NuCana PLC | -11.24M |
| Autolus Therapeutics PLC | 95.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.927B |
| Revenue (Quarterly) | 12.94B |
| Total Expenses (Quarterly) | 10.19B |
| EPS Diluted (Quarterly) | 1.24 |
| Gross Profit Margin (Quarterly) | 83.13% |
| Profit Margin (Quarterly) | 14.89% |
| Earnings Yield | 3.18% |
| Operating Earnings Yield | 4.83% |
| Normalized Earnings Yield | 3.468 |